Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis.

Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols / adverse effects Carcinoma, Non-Small-Cell Lung / pathology Humans Lung Neoplasms / pathology Network Meta-Analysis
Chemotherapy Network meta-analysis Non-small-cell lung cancer Pembrolizumab Survival Systematic review

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
May 2022
Historique:
received: 10 06 2021
revised: 21 03 2022
accepted: 21 03 2022
pubmed: 29 3 2022
medline: 3 5 2022
entrez: 28 3 2022
Statut: ppublish

Résumé

Pembrolizumab monotherapy has replaced chemotherapy as first-line treatment for patients with metastatic non-small-cell lung cancer with tumor programmed death-ligand 1 expression ≥ 50%. The benefit of chemotherapy combined with pembrolizumab, as compared to pembrolizumab monotherapy, remains uncertain. This systematic review and network meta-analysis aimed to compare these therapies through a network of randomized controlled trials. Endpoints evaluated were progression-free survival (PFS) and overall survival (OS) expressed as hazard ratio (HR) and restricted mean survival time (RMST) through reconstruction of individual patient data from Kaplan-Meier curves, and objective response rate and adverse events. Four trials were included. Through HR and RMST, combination therapy demonstrated longer PFS and similar OS as compared to pembrolizumab monotherapy. Combination therapy was associated with an increase in response rate and adverse events. Thus, combination therapy can be considered when rapid response or prevention of rapid progression is needed. Further evidence to directly compare these therapies is required.

Identifiants

DOI: 10.1016/j.critrevonc.2022.103660 PMID: 35341985
pubmed: 35341985
pii: S1040-8428(22)00084-1
doi: 10.1016/j.critrevonc.2022.103660
pii:
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
pembrolizumab DPT0O3T46P

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103660

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Suji Udayakumar (S)

Sunnybrook Research Institute, Toronto, ON, Canada.

Ambica Parmar (A)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.

Natasha B Leighl (NB)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Louis Everest (L)

Sunnybrook Research Institute, Toronto, ON, Canada.

Vanessa S Arciero (VS)

Sunnybrook Research Institute, Toronto, ON, Canada.

Seanthel Delos Santos (SD)

Sunnybrook Research Institute, Toronto, ON, Canada.

Amanda Rahmadian (A)

Sunnybrook Research Institute, Toronto, ON, Canada.

Mark K Doherty (MK)

Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.

Kelvin K W Chan (KKW)

Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada; Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada. Electronic address: kelvin.chan@sunnybrook.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Pembrolizumab alone or with chemotherapy for...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Pembrolizumab alone or with chemotherapy for...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Pembrolizumab alone or with chemotherapy for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pembrolizumab alone or with chemotherapy for...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Pembrolizumab alone or with chemotherapy for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méta-analyse comme sujet › Méta-analyse en réseau › Pembrolizumab alone or with chemotherapy for...